A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor

The PI3K–AKT pathway is expected to be a therapeutic target for non-small cell lung cancer (NSCLC) treatment. We previously reported that a novel PI3K inhibitor iMDK suppressed NSCLC cells in vitro and in vivo without harming normal cells and mice. Unexpectedly, iMDK activated the MAPK pathway, incl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Exp Cell Res
Main Authors: Ishida, Naomasa, Fukazawa, Takuya, Maeda, Yutaka, Yamatsuji, Tomoki, Takaoka, Munenori, Haisa, Minoru, Yokota, Etsuko, Shigemitsu, Kaori, Morita, Ichiro, Kato, Katsuya, Matsumoto, Kenichi, Shimo, Tsuyoshi, Okui, Tatsuo, Bao, Xiao-Hong, Hao, Huifang, Grant, Shawn N., Takigawa, Nagio, Whitsett, Jeffrey A., Naomoto, Yoshio
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4485577/
https://ncbi.nlm.nih.gov/pubmed/25839409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.yexcr.2015.03.019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados